retatrutide phase 2 trial obesity nejm 2023 in adults with over 104 weeks in the highest dose group had 30.3% weight loss. Nearly 2/3 reached BMI < 30 1 in 3 reached BMI < 25 Retatrutide (not yet approved in

Quality considerations for compounded formulations If you are using compounded semaglutide with glycine, the quality of your formulation depends entirely on the pharmacy that produces it

The race to generics and alternatives Novo Nordisks first GLP-1 drug liraglutide will be off patent in November and in June Teva Pharmaceuticals received US authorisation to market the first-ever generic version, to treat diabetes

Health Canada is likely to approve it closer to 2028

More steady energy during the day can help individuals maintain longer workouts without tiring too early

All information presented here is not meant as a substitute for or alternative to information from health care practitioners